Hualan Biological Engineering Inc
SZSE:002007

Watchlist Manager
Hualan Biological Engineering Inc Logo
Hualan Biological Engineering Inc
SZSE:002007
Watchlist
Price: 16.48 CNY 0.18% Market Closed
Market Cap: 30.1B CNY
Have any thoughts about
Hualan Biological Engineering Inc?
Write Note

Hualan Biological Engineering Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hualan Biological Engineering Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Hualan Biological Engineering Inc
SZSE:002007
Cash from Financing Activities
-ÂĄ483.6m
CAGR 3-Years
N/A
CAGR 5-Years
-13%
CAGR 10-Years
-11%
Beigene Ltd
HKEX:6160
Cash from Financing Activities
ÂĄ2.6B
CAGR 3-Years
-57%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Cash from Financing Activities
ÂĄ960.9m
CAGR 3-Years
-31%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash from Financing Activities
-ÂĄ893.3m
CAGR 3-Years
N/A
CAGR 5-Years
-98%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Cash from Financing Activities
-ÂĄ1.2B
CAGR 3-Years
-25%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash from Financing Activities
-ÂĄ2B
CAGR 3-Years
24%
CAGR 5-Years
-38%
CAGR 10-Years
-39%
No Stocks Found

Hualan Biological Engineering Inc
Glance View

Market Cap
30.1B CNY
Industry
Biotechnology

Hualan Biological Engineering, Inc. engages in the research and development, production, and sale of biological products. The company is headquartered in Xinxiang, Henan and currently employs 2,927 full-time employees. The company went IPO on 2004-06-25. The company also produces vaccine products and biological engineering products. The firm's main products include human albumins, human immunoglobulin for intravenous injection, human immunoglobulin, human coagulation factors, human rabies immunoglobulin, human tetanus immunoglobulin and influenza vaccines, among others. The firm mainly operates its businesses in domestic markets.

Intrinsic Value
26.95 CNY
Undervaluation 39%
Intrinsic Value
Price

See Also

What is Hualan Biological Engineering Inc's Cash from Financing Activities?
Cash from Financing Activities
-483.6m CNY

Based on the financial report for Sep 30, 2024, Hualan Biological Engineering Inc's Cash from Financing Activities amounts to -483.6m CNY.

What is Hualan Biological Engineering Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-11%

Over the last year, the Cash from Financing Activities growth was 5%.

Back to Top